Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) COO Sells 2,793 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen M. Oelschlager sold 2,793 shares of Castle Biosciences stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $22.06, for a total value of $61,613.58. Following the sale, the chief operating officer now directly owns 145,825 shares in the company, valued at $3,216,899.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Castle Biosciences Stock Performance

NASDAQ:CSTL opened at $24.13 on Thursday. Castle Biosciences, Inc. has a 1 year low of $12.07 and a 1 year high of $25.91. The firm has a 50 day moving average of $21.52 and a 200-day moving average of $21.79. The company has a current ratio of 9.25, a quick ratio of 9.02 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Thursday, May 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.91%. The company had revenue of $72.97 million during the quarter, compared to analysts’ expectations of $68.34 million. Equities research analysts expect that Castle Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its stake in shares of Castle Biosciences by 7.0% in the fourth quarter. Principal Financial Group Inc. now owns 1,585,673 shares of the company’s stock valued at $34,219,000 after acquiring an additional 103,503 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Castle Biosciences by 2.2% in the first quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock valued at $33,096,000 after acquiring an additional 32,695 shares during the last quarter. Bellevue Group AG raised its stake in shares of Castle Biosciences by 0.4% in the fourth quarter. Bellevue Group AG now owns 1,232,378 shares of the company’s stock valued at $26,595,000 after acquiring an additional 4,347 shares during the last quarter. Parkman Healthcare Partners LLC raised its position in Castle Biosciences by 59.0% in the 4th quarter. Parkman Healthcare Partners LLC now owns 357,156 shares of the company’s stock worth $7,707,000 after purchasing an additional 132,564 shares during the last quarter. Finally, Intrinsic Edge Capital Management LLC raised its position in Castle Biosciences by 108.8% in the 4th quarter. Intrinsic Edge Capital Management LLC now owns 326,270 shares of the company’s stock worth $7,041,000 after purchasing an additional 170,000 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Robert W. Baird reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Castle Biosciences in a report on Friday, July 5th.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.